MJFF Grant Portal block (Pre-Proposals / Coordinating Lead PI / Full Proposal Invitations), MJF imaging meeting along with MJFF, WORKSHOP 202111 day2 conference slide, Canada / PDGENeration / Stephenson 2019 / Rare Disease Data Registry of Japan / Dr. Takeda AMED contacts, ATCs (Contacts) table opener (Soon Chung / Riley Frilghity / Rae Estrella / Won Lee / Jaewon Lee / Jaya Rosen / Jeffrey Knight / Leonis Papakosta / Zach McQuade / Toro Tomimatsu)
MJFF Grant Portal — Outcome Measures
Pre-Proposals Due: October 22, 2020, 5 p.m. US ET (completed submission of the proposal to MJFF on Oct 21)
Anticipated Award Announcement: Week of November 14, 2020.
- Full Proposal Invitations: December 11, 2020
- Full Proposals Due (by invite only): March 18, 2021, 5 p.m. US ET
- Anticipated Award Announcement: Week of May 31, 2021
MJFF Grant Portal: Contact [email protected] : grants.michaeljfox.org (구 https://mjff.smartsimple.com)
- Application guideline (including budget) https://www.michaeljfox.org/news/application-
Can you switch PI’s after submitting a Pre-Proposal?
Yes, the Principle Investigator can be changed at the full application stage. Please note, the new Principle Investigator will have to meet the eligibility requirements for the program they are applying for. The Same Application Form requires must account must be used during pre-proposal and full application submissions.
What does it mean to be a Coordinating Lead Principal Investigator?
The Coordinating Lead Principal Investigator is responsible for the scientific and technical direction of the proposed research project, contractual and financial obligations, and other organizational assurances/certifications. This person must ensure the Principal Investigator (PI) Comply with the terms and conditions of the award and will be the primary contact person for ASAP scientifically supported responsibilities are with the corresponding Principal Investigator. It is highly recommended that the Coordinating Lead PI must be affiliated with the institution submitting the application grant funds will be awarded to that institution, which will take responsibility for distributing funds to the institutions of the other members of the collaboration.
- PI receipt
- PI vs nondag, vs process
- We may also decide to fund only the portion of the proposal that fits (‘s the call)
- (또는 NIH 의 principal investigator (PA) ? 가 별도, budget?)
- Enabler? 부 LOI 가 있다 secure, and then give up?
- Q (Q rejection
- PI requirement, academia only? Blank ok?
- Staged studies.
| MJFF | Takeda | |
|---|---|---|
| Coordinating institution, grantees, pass-through | MJFF | Takeda |
| Subaward, subrecipient | CRO | Funding itself |
MJF imaging meeting along with MJFF
202305 annual PPMI investigator meeting
WORKSHOP 202111 day2 (02:58 on recording)
- Pathological aSyn aggregation with small molecule oligomer modulator: anle138b (MODAG)
- One ALLOSTERIC REGULATOR - Gain therapeutics
- Mini-3 Acure therapeutics
- PEGylated Sanofi-3 Modag therapeutics
- Mini-3 Acure therapeutics
- GM-CSF (PIM808), AN immunomodulatory approach, Carlo at Scripps Research
- cellularity Tx? creating new vectors - LICCD
- Weekly PDX: https://app.box.com/team7pbm0kb6n6oh40p1d2eb22276x6jaj
Canada — The Neuro
- Montreal Neurological Institute - Hospital
- https://www.mcgill.ca/neuro/
- Open Science
PDGEN-eration
Sanofi and the Parkinson’s Foundation, At-Home Testing https://www.parkinson.org/PDGENeration?ga=2.114923651.280508187.1602364691-126865791.1602514568
- 3000 people genotyped, and about 60-70 who received a positive PRKN result - https://compound.hubs/homozygotes
(Stephenson, 2019 #1282)
oligomer map of the PD brain over 15 disease-relevant regions and over different cell type (single cell RNA seq), - linMaro? complex structure of single cell data, in CSF, ar to thoroughness, by SNP/IF dB, 7%, oligomer presence. Six SNPs in the LICs?
- QUESTION: FUND? WHY Oligomers?
-validation- iPSC+oligomer→ readouts: ROS, mito, Ca, synapse, UPR, oligomer flux
Rare Disease Data Registry of Japan
https://www.raddar.org/en/about/
PI: Hidemasa Sasaki (retired) at Hokkaido. https://neurology.med.hokudai.ac.jp/-hu-uw-w/-hu-mu
Dr. Takeda, AMED
(Otaki) we have performed RNA-seq on both CSF-EV and NDE from control, MCI and AD groups. However, I’m sorry that distribution of individual gene expression data and other clinical information is limited only to the participants in compliance with the contract with Osaka University and AMED. This four year collaboration will be finished in a month and after that we will be encouraged from AMED to make the data open access more by publication. If just seeking specific genes of interest and let you the data by post or statistical test would be grey area.
ATCs (Contacts)
| name | contact | |
|---|---|---|
| Soon Chung | Takeda Pharmaceutical Company Limited 40 Landsdowne Street Cambridge, MA 02139 United States of America | +1-857-204-8431 |
| Riley Frilghity | 781-428-5601 | |
| Rae Estrella | 734-883-8167 | |
| Won Lee | 9625 Towne Centre Dr. San Diego, CA 92121, Takeda Development Center Americas, Inc. (TDCA) (office TCD3800-P) +1 619-9230-8351 [email protected] | |
| Jaewon Lee | 9625 Towne Centre Dr. San Diego, CA 92121 Takeda Development Center Americas, Inc. (TDCA) (office TCD3800-Y) YAGUCHIDAI 54-11, NAKA-KU, YOKOHAMA-SHI, KANAGAWA Japan postcode 231-0831 office +81 (3) 54-11 +81 7-231-0831 <[email protected]> +1 (978) 808-3174 | |
| Jaya Rosen | cell 484-547-4729 Takeda Cambridge MA 02139 Floor 7 Office +1 +1-444-1334 +1 484-547-4729 (Kendall S Cambridge, MA 02139 - state of Massachusetts is a county) | |
| Jeffrey Knight | 81-70-1253-0648 | |
| Leonis Papakosta | Takeda Development Center Americas, Inc. (TDCA) 9625 Towne Centre Dr. San Diego, CA 92121 / USA 781 250 9704 Office +1 (978) 930-8110 | |
| Zach McQuade | 617-308-3182 [email protected] Takeda Cambridge MA 02142 / 10th Floor (215) 200-8678 | |
| Toro Tomimatsu | +1 (870) 4277124-7 | |
| PTM Contact CRO | cell.tom@m |
Uncertain Spans
| location | transcription | uncertainty |
|---|---|---|
| Stephenson 2019 cell | linMaro? complex structure of single cell data, in CSF, ar to thoroughness, by SNP/IF dB, 7% | mixed Korean / English narrative with OCR artefacts; preserved verbatim. |